AR111823A1 - MIC-1 COMPOUNDS AND THEIR USES - Google Patents
MIC-1 COMPOUNDS AND THEIR USESInfo
- Publication number
- AR111823A1 AR111823A1 ARP180101367A ARP180101367A AR111823A1 AR 111823 A1 AR111823 A1 AR 111823A1 AR P180101367 A ARP180101367 A AR P180101367A AR P180101367 A ARP180101367 A AR P180101367A AR 111823 A1 AR111823 A1 AR 111823A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- mic
- acid extension
- compounds
- protractor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title abstract 4
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
También se refiere a composiciones farmacéuticas que comprenden tales compuestos y excipientes farmacéuticamente aceptables, así como el uso médico de los compuestos. Reivindicación 1: Un compuesto de MIC-1 que comprende un polipéptido de MIC-1 con una extensión de aminoácido N-terminal y un protractor, en donde dicho protractor está unido a dicha extensión de aminoácido y en donde la extensión de aminoácido consiste en 3 a 36 residuos de aminoácidos y dicho polipéptido de MIC-1 con dicha extensión de aminoácido tiene un pl calculado inferior a 6,5. Reivindicación 15: Compuesto de acuerdo con cualquiera de las reivindicaciones 1 - 14 para usar en la prevención y/o el tratamiento de un trastorno metabólico, en donde el trastorno metabólico es obesidad, diabetes, enfermedad cardiovascular como dislipidemia, arteriosclerosis, esteatohepatitis o nefropatía diabética.It also refers to pharmaceutical compositions comprising such pharmaceutically acceptable compounds and excipients, as well as the medical use of the compounds. Claim 1: A MIC-1 compound comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor, wherein said protractor is attached to said amino acid extension and wherein the amino acid extension consists of 3 at 36 amino acid residues and said MIC-1 polypeptide with said amino acid extension has a calculated pl of less than 6.5. Claim 15: Compound according to any one of claims 1-14 for use in the prevention and / or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, diabetes, cardiovascular disease such as dyslipidemia, arteriosclerosis, steatohepatitis or diabetic nephropathy .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017085576 | 2017-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111823A1 true AR111823A1 (en) | 2019-08-21 |
Family
ID=67766484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101367A AR111823A1 (en) | 2017-05-23 | 2018-05-23 | MIC-1 COMPOUNDS AND THEIR USES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR111823A1 (en) |
-
2018
- 2018-05-23 AR ARP180101367A patent/AR111823A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019005924A2 (en) | Dual acylated agonists of glp-1 / glp-2 | |
| MX2022007607A (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors. | |
| GT201400166A (en) | SYNTHETIC APELINE MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT | |
| MX2020009856A (en) | RIMEGEPANT FOR CALCITONIN GENE-RELATED PEPTIDE (CGRP)-RELATED DISORDERS. | |
| CL2018003319A1 (en) | Mic-1 compounds and uses of these. | |
| CL2019002132A1 (en) | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and their uses. | |
| CL2017003185A1 (en) | Co-agonist compounds of glucagon and glugacon-like peptide-1 (glp-1) | |
| CL2012003226A1 (en) | Compounds derived from 5-fluoro-1h-pyrazolopyridine; preparation procedure for these; framaceutic composition that understands them; and its use in the treatment of cardiovascular, sexual and metabolic diseases. | |
| MX2017015105A (en) | SELECTIVE YY (PYY) PEPTIDE COMPOUNDS AND THEIR USES. | |
| CL2017000201A1 (en) | Compositions and methods of use to treat metabolic disorders | |
| CR20150149A (en) | FUSION PROTEINS FOR THE TREATMENT OF A METABOLIC SYNDROME | |
| CL2012001722A1 (en) | Compounds derived from 3-hydroxy-5-arylisothiazole, agonists of receptor 40 coupled to protein g (gpr40); pharmaceutical composition comprising them; and method for the treatment or prevention of diabetes. | |
| EA201791281A1 (en) | CONNECTIONS-COAGONISTS GUI And GLP-1 | |
| CL2011003003A1 (en) | Reconstituted surfactant composition comprising a native surfactant protein c-analog polypeptide, a native surfactant protein-b-analog polypeptide, a monounsaturated phospholipid, and a saturated phospholipid, useful for the treatment of respiratory distress syndrome. | |
| UY37098A (en) | ROR-GAMMA MODULATORS | |
| CL2013002414A1 (en) | Compounds derived from cyclic azabenzimidazole, activators of amp-activated protein kinase; pharmaceutical composition that includes them; and its use for treatment or disease such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and hypertension. | |
| PE20171622A1 (en) | INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION | |
| CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
| PE20170470A1 (en) | METHODS AND COMPOSITIONS TO TREAT OBESITY, PREVENT WEIGHT GAIN, PROMOTE WEIGHT LOSS, PROMOTE SLIMMING, OR TREAT OR PREVENT THE DEVELOPMENT OF DIABETES | |
| CL2017001843A1 (en) | Lixisenatide and / or a pharmaceutically acceptable salt thereof for the treatment of pediatric patients with type 2 diabetes mellitus. | |
| CU20210008A7 (en) | SOLUBILIZED ASPIRASES | |
| AR111374A1 (en) | USE OF LIK066 IN PATIENTS WITH HEART FAILURE | |
| CO2019004131A2 (en) | Metformin glycinate, pharmaceutical compositions comprising the same, and methods of use thereof | |
| CL2017002326A1 (en) | Treatment of patients with type 2 diabetes mellitus | |
| EA201992562A1 (en) | PEPTIDES FOR THE TREATMENT OF DIABETES MELLITUS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |